RBC Capital raised the firm’s price target on Verrica Pharmaceuticals to $14 from $11 and keeps an Outperform rating on the shares. The firm states that it continues to see an opportunity on commercial prospects now that a major regulatory clearing event has passed, adding that it is a “buyer on weakness” given the clarifying launch path of YCANTH in molluscum contagiosum, drug profile, and end-market potential.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VRCA:
- Verrica Pharmaceuticals upgraded to Buy from Hold at Needham
- Verrica Pharmaceuticals director buys $1.0M in common stock
- Verrica Pharma (NASDAQ:VRCA) Tanks on $125M Debt Financing Plan
- Verrica enters non-binding term sheet for up to $125M debt financing
- Following FDA Approval of YCANTH™ for the Treatment of Molluscum Contagiosum, Verrica Pharmaceuticals Enters into Non-Binding Term Sheet for up to $125 Million Debt Financing; Company to Host Conference Call and Webcast This Morning at 8:30 am ET
